We describe a case of disseminated Mycobacterium tuberculosis (mTB) with prostatic abscess in a newly diagnosed HIV patient in the United States. The patient is a 34 year-old male who presented with respiratory symptoms and was diagnosed with HIV/AIDS complicated by disseminated mTB infection of the lungs, liver, and prostate. His prostate showed abscess formation on imaging that required drainage however he did not present with any genitourinary complaints. Our literature review revealed that prostatic involvement in mTB in the form of granulomatous prostatitis is uncommon; however, abscess formation is extremely rare and only few such cases have been published. Nearly 50% of the patients with prostatic abscess formation present without symptoms and therefore a high level of suspicion should be maintained; imaging should be performed early and prophylactic antibiotics for non-specific urinary symptoms should be avoided as this may lead to drug resistance of mTB to flouroquinolones.
Introduction
Disseminated tuberculosis is defined as the spread of Mycobacterium tuberculosis complex (mTB) to one or more organs via hematogenous or lymphatic spread [12] . Even though pulmonary system involvement is most common, extrapulmonary involvement is seen in 10% of cases. Of which 30-40% of the patients with extrapulmonary involvement will present with genitourinary tuberculosis (GU TB) [9] . Amongst the GU organs, prostatic TB is less common (<5%). Overall, the largest study of prostatic TB prevalence was done by Sporer et al. where 100 cases of prostatic TB were identified out of 728 disseminated TB autopsy cases [28] . These cases included prostatic involvement in the form of granulomatous prostatitis and prostatic abscesses. Prostatic abscesses are less common and only 5 such cases have been reported in the United States [10, 11, 15, 24, 29, 30] . In this case report, we present a case of disseminated TB, including a prostatic abscess, in a patient with new diagnosis of HIV. In addition, we review the literature on prostatic abscess formation by mTB to identify prevalence, symptomatology, treatment and prognosis of these patients.
Case report
A 34-year-old Indonesian male presented with a four week history of diffuse abdominal pain, nausea, vomiting, odynophagia, dyspnea on exertion, and a 20-pound unintentional weight loss. The patient had a past medical history significant for intravenous drug abuse, alcohol abuse and 15 packs per year smoking history. The patient had moved to United States from Indonesia 7 years ago. Physical exam revealed a cachectic male with oropharyngeal candidiasis and crackles bilaterally. Diffuse abdominal tenderness on palpation was also noted. Laboratory studies revealed a normal complete blood count (CBC), hyponatremia with sodium of 122 mEq/L, and abnormal liver function tests: AST 442 U/L, ALT 150U/L, and ALP 295 U/L. A fourth-generation HIV antigen/ antibody test (Abbott Laboratories) was confirmed positive with a MultiSpot positive for HIV-1 antibodies. Hepatitis C antibody testing was also reactive. Additional testing revealed a CD4 count of 2 cells/mm 3 and a HIV-1 titer of 427,000 copies/ml determined by a Quantitative HIV-1 RNA PCR assay (COBAS AmpliPrep/COBAS Taqman Analyzer, v2.0, Roche Diagnostics). Chest imaging was concerning for either multifocal pneumonia and/or possible opportunistic infection (Fig. 1A) . Abdominal CT revealed necrotic mesenteric lymphadenopathy (Fig. 1B) , micro-abscesses in the liver (Fig. 1C) , and a 2.9 Â 2.4 Â 2.0 cm fluid attenuation collection posterolateral to the prostate suggestive of an abscess ( Fig. 1D-E) . Urine analysis showed 2+ protein, 1+ urobilinogen, 3 red blood cells, and 2 white blood cells. Multiple routine urinary cultures showed no growth. Three sputum samples were collected and all showed 4+ acid-fast bacilli (AFB) (> 36 AFB organisms per field of view at 400 Â magnification) by auramine-rhodamine stain and grew pure Mycobacterium tuberculosis complex in less than 7 days post-collection in the BACTEC TM Mycobacterial Growth Indicator Tube (MGIT). Following culture, drug sensitivity testing was performed, and the mTB isolate was susceptible to first line drugs, including isoniazid (MIC-0.2 mcg/mL), rifampin (MIC-1.0 mcg/mL), ethambutol (MIC-5.0 mcg/mL), pyrazinamide (MIC-100 mcg/mL) and streptomycin (MIC-2.0mcg/mL). The patient was started on rifampin-300 mg twice daily, isoniazid-300 mg daily, pyrazinamide-1500 mg daily and ethambutol-1200 mg daily (RIPE therapy). Antiretroviral therapy was not initiated at this time. Twelve days later, on follow-up imaging, the prostatic abscess remained unchanged and a CT guided approach was utilized to drain the abscess. Purulent fluid (2 mL) was drained and sent for AFB culture. The purulent fluid revealed 4+ AFB by auraminerhodamine stain ( Fig. 2A) and grew mTB complex. The direct Kinyoun stain is shown in Fig. 2B . Patient clinically improved on RIPE therapy and was discharged with isolation precautions. 3 weeks post discharge, antiretroviral therapy with dolutegravir and Truvada (HAART) was initiated. Post-discharge (28 days), the patient was brought to the emergency department with acute onset of drowsiness and incomprehensible speech. The patient had been compliant with his medications. At this point, differential diagnosis of Immune reconstitution inflammatory syndrome (IRIS), and a new opportunistic infection including toxoplasmosis were considered. MRI of the brain revealed multiple ring enhancing lesions with surrounding edema in the cerebral hemispheres bilaterally, the midbrain, and the cerebellar hemispheres bilaterally as well (Fig. 3A,B) . The patient was started on steroids, empiric toxoplasmosis therapy with pyrimethamine, sulfadiazine, and folinic acid. HAART and mTB therapy were continued. A lumbar puncture was performed that showed cerebrospinal fluid glucose of 54, protein of 116, RBC count of 7, and WBC count of 0. The cryptococcal antigen was non-reactive. Toxoplasmosis IgG was >5; however, Toxoplasma gondii PCR was negative. The patient's hospital stay was also complicated by both hyponatremia and also hypertension attributed to SIADH. The patient gradually improved on the aforementioned therapeutic regimen and nearly two months later, brain MRI showed a decrease in the size of the lesions. The patient's mental status also improved and the patient was deemed fit for discharge. The patient was lost to follow-up after relocating to another state.
Discussion
We report a rare case of disseminated mTB with a prostatic abscess in the United States in a newly diagnosed patient with AIDS. The patient group most commonly afflicted with disseminated mTB is the HIV/AIDS population (50-70%) [20] . As discussed, involvement of the prostate is less common than involvement of other GU organs [14] . When present, prostatic mTB commonly manifests as granulomatous prostatitis. Literature review of prostatic TB cases shows that prostatic abscess formation is exceedingly rare. Worldwide, approximately 21 such cases have been reported in the literature with most case reports from India and Spain and only 5 such cases from United States (Table 1) [1, 3, 4, 7, 8, 16, 17, 19, 23, [25] [26] [27] .
Even though majority of the patients with GU mTB present with symptoms of dysuria, changes in urinary flow, urgency or frequency, nearly 25% of the patients present with no GU symptoms [22] . In the review of literature, amongst the patients with prostatic abscesses, 11/21 patients presented with urinary symptoms (52%). In our patient, no GU complaints were documented and the prostatic abscess was an incidental finding on CT of the abdomen and pelvis. Prostate specific antigen (PSA) testing is not usually helpful since only rare instances of PSA elevation have been noted in patients with GU involvement Lanjewar and Maheshwari, 1994 . Commonly, sterile pyuria and hematuria are the most common findings. A high rate of suspicion should be maintained in HIV/immunocompromised patients presenting with urinary symptoms. It is important to not treat dysuria symptoms in these patients with empiric antibiotic therapy such as with fluoroquinolones for presumable bacterial UTI as this can lead to drug resistance to mTB as they have activity against mTB [13] .
Since mTB is acquired person through person through aerosolized droplets, the infection initially affects the pulmonary system. In an immunocompetent patient, granuloma formation around the bacilli within the lung parenchyma can contain mTB replication and prevent disease activation. However, in immunocompromised patients, specifically AIDS patients, granuloma formation is inadequate due to altered functionality of CD4 T cells, macrophages, dendritic cells, neutrophils and fibroblasts [6] . These immune-microenvironment alterations allow for uncontrolled mTB replication, higher chances of getting active infection and distant spread. GU spread occurs through lymphatic spread, hematogenous seeding, descending infection to urinary organs or tract, direct extension from neighboring TB focus in the genital tract, and rarely ascending infection through the urethra in cases of BCG therapy. One or successive hematogenous seedings are the most common mode of transmission Sporer and Auerbach, 1978 . Typically an extended (long) latency period of approximately 22 years exists between the first pulmonary infection and presentation of GU mTB Figueiredo and Lucon, 2008 . Incongruously, in this case, the patient presented with pulmonary involvement and was diagnosed with disseminated TB including hepatic, splenic, lymphatic and prostatic involvement simultaneously. Common predisposing factors to prostatic abscess formation in disseminated mTB include immunosuppression whether it is in the form of impaired cell mediated immunity, acquired immunodeficiency syndrome (AIDS) as in this case, prolonged immunosuppressants, or steroid use. Other patient populations at risk for disseminated mTB, even though much more infrequent, include patients with previous BCG therapy for bladder carcinoma and immunocompetent patients. During the literature review, we noted different patterns of mTB dissemination in these three different patient populations. Most of the immunocompetent patients with prostatic abscesses had isolated prostate involvement by mTB (5/6). Only one case report documented involvement of the prostate as part of disseminated TB, in an immunocompetent host. In the BCG therapy population, 2/3 patients had isolated prostate involvement with one developing miliary TB [7] . Lastly, amongst the HIV/immunocompromised population, 4 patients had disseminated disease alongside prostatic abscess formation while 11 patients had prostate only involvement [1, 8, 23, 24] . It can be theorized that the cases with disseminated TB including prostatic abscess are likely under-reported in literature because extent of visceral organ involvement even when present may not be welldelineated or documented in such cases. These findings raise a crucial clinical management issue-since immunocompromised patients, particularly AIDS patients are at high risk for developing prostatic abscess, it is crucial to get a transrectal ultrasound, CT or MRI of the abdomen and pelvis to rule-out abscess formation. In our patient, even though the prostatic abscess was identified early, RIPE therapy could not penetrate the abscess wall and despite weeks of treatment, the prostatic abscess imaging remained unchanged. The standard of care therapy for these patients should include prostatic abscess drainage in addition to mTB therapy as was done in our case. Majority of the cases in the literature review were treated similarly and did well. Only one patient died during RIPE therapy and that was attributed to central nervous system involvement by mTB.
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Conclusion
Here, we presented a case of prostatic abscess formation as part of disseminated TB in a patient with no GU symptoms and a new AIDS diagnosis. In AIDS patients, it is important to keep a high index of suspicion for prostatic abscess formation, perform imaging early, avoid prophylactic antibiotics without culture proven urinary tract infection, and treat with drainage and mTB therapy. 
